| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.8 | 0.7 |
| Profit before tax | -21.5 | -31.5 |
| Net income | -21.9 | -31.5 |
| EPS (diluted, $ a share) | $-2.09 | $-3.04 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +281.9% |
|---|
10-Q filed with the SEC, NASDAQ: ALGS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Aligos Therapeutics, Inc.: key numbers
- Share price
- $1.36Close, Nov 17
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Aligos Therapeutics, Inc.
All →Aligos Therapeutics Financial Results
Aligos Therapeutics reported third quarter 2026 financial results, including a net loss of $21.9 million and a cash position of $31.1 million. The company highlighted clinical progress in its Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for a topline data readout in late Q3 2027. Current cash reserves are expected to fund operations into the first quarter of 2027.
“This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout in late Q3 2027. With enrollment complete and 70 participants having completed 48 weeks of treatment, the study continues to progress toward the anticipated topline data readout. We remain enthusiastic about pevifoscorvir sodium’s potential, as well as our ASO ALG-170675, which is currently in a Phase 1 study in China with our partner Amoytop. With these recent developments, we believe we are one step closer to our goal of bringing effective therapies to people living with chronic HBV infection.”
Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer
Aligos Therapeutics Other 8-K Filing
Aligos Therapeutics entered into a first amendment to its headquarters lease in South San Francisco, extending the term from March 2027 to March 2034. The amendment sets a graduated monthly base rent starting at $4.650 per square foot and includes a ten-month rent abatement period and a one-time termination option in 2031.
- Counterparty
- Britannia Biotech Gateway Limited Partnership
- Term
- 7 years